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Abstract Mantle cell lymphoma (MCL) has a heteroge-
neous clinical course and is mainly an aggressive B cell
non-Hodgkin lymphoma; however, there are some
indolent cases The Ki-67 index, defined by the
percentage of Ki-67-positive lymphoma cells on histo-
pathological slides, has been shown to be a very
powerful prognostic biomarker. The pathology panel of
the European MCL Network evaluated methods to
assess the Ki-67 index including stringent counting,
digital image analysis, and estimation by eyeballing.
Counting of 2×500 lymphoma cells is the gold standard
to assess the Ki-67 index since this value has been
shown to predict survival in prospective randomized
trials of the European MCL Network. Estimation by
eyeballing and digital image analysis showed a poor
concordance with the gold standard (concordance correla-
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Barcelona, Spaintion coefficients [CCC] between 0.29 and 0.61 for
eyeballing and CCC of 0.24 and 0.37 for two methods
of digital image analysis, respectively). Counting a
reduced number of lymphoma cells (2×100 cells) showed
high interobserver agreement (CCC=0.74). Pitfalls of the
Ki-67 index are discussed and guidelines and recommen-
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Introduction
Mantle cell lymphoma (MCL) is a distinct B cell non-
Hodgkin lymphoma with a poor clinical long-term
outcome [1]. The currently used intensive treatment
protocols including anti-CD20 antibody and autologous
stem cell transplantation increased the response rate and
remission duration but have failed to improve long-term
overall survival so far [12]. The poor clinical outcome and
the high number of relapses have stimulated research for
alternative chemotherapeutic approaches for patients after
a relapse and for high-risk patients as an alternative
frontline therapy [12].
MCL is characterized by the translocation t(11;14)
(q13;q32), which juxtaposes the immunoglobulin heavy-
chain gene to the gene for cyclin D1 [8]. As a
consequence of the translocation, cases of MCL show
constitutive upregulation of cyclin D1 expression. Since
cyclin D1 promotes the transition from the G1 to S phase
of the cell cycle, MCLs are characterized by cell cycle
deregulation [8]. The cell proliferation rate, as measured
by the Ki-67 index (the percentage of Ki-67-positive
tumor cells), is correlated with the level of cyclin D1
expression and other cell cycle regulators [16].
The Ki-67 index has been confirmed as a very
powerful single prognostic factor for overall survival,
with highly proliferative cases showing a much poorer
outcome than tumors with low proliferation [21].
Recently, we demonstrated that the Ki-67 index retains
its prognostic relevance in randomized prospective trials
employing immunochemotherapy with the anti-CD20
antibody rituximab [6]. Moreover, using the Ki-67 index
in combination with clinical parameters such as age,
performance status, lactate dehydrogenase, and leukocyte
count (Mantle Cell Lymphoma International Prognostic
Index), we were able to design a combined clinicobio-
logical prognostic index for MCL [9]. Defining clinical
risk scores might help to design patient-specific and
lymphoma-specific therapy.
So far, in most of the published studies of other
tumors, the stainings for Ki-67 were evaluated in a
single center or by very few observers, thus avoiding
the problem of interobserver variability. However, in
order to allow the application of the Ki-67 index in
clinical routine management of MCL with cut-off points
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or incorporation of the Ki-67 index as a continuous
variable in a prognostic index [9], it is of the highest
importance to unify methods and establish guidelines for
Ki-67 assessment. For this purpose, the pathology panel of
the European MCL Network compared different methods
of assessing the Ki-67 index on samples from patients
with advanced-stage MCL treated within the randomized
trials of European MCL Network and German Low Grade
Lymphoma Study Group (GLSG). We provide recommen-
dations and guidelines for the future use of the Ki-67
i n d e xi nM C L .
Materials and methods
Lymphoma samples
Thirty-two primarydiagnosticlymphnodebiopsyspecimens
from different patients with advanced-stage MCL treated
within the clinical trials of the European MCL Network and
GLSG[7, 13, 14] were randomly chosen. The stainings for
Ki-67 were performed in different laboratories using
diverse techniques and antibody clones, namely, Berlin
(n=10, Mib-1 antibody, alkaline phosphatase–antialkaline
phosphatase method; Dako, Glostrup, Denmark), Kiel (n=
7, Ki-S5 antibody, alkaline phosphatase–antialkaline
phosphatase method, home-brewed reagents), Lübeck
(n=2, Mib-1 antibody, Envision method; Dako, Glostrup,
Denmark), and Würzburg (n=13, Mib-1 antibody, Envi-
sion method; Dako, Glostrup, Denmark). Only slides
which showed unambiguous strong nuclear staining were
analyzed. Therefore, three cases had to be excluded,
resulting in 29 evaluable cases.
Ki-67 index
The Ki-67 index was defined as the percentage of Ki-67-
positive tumor cells in representative areas (see below) of
the lymphoma and was evaluated by counting, eyeballing,
and digital image analysis.
Counting
Counting was performed by one observer (O.D.). To count
the number of Ki-67-positive cells, two representative areas
were chosen. A representative area was defined not to
contain residual germinal centers, hot spots of proliferation
or proliferating T cells. Hot spots of proliferation are areas
of tumor cells (not germinal center residues) of less than
two high-power fields in size (HPF, field of vision at ×400
magnification), which proliferate higher than the rest of the
tumor. Usually, hot spots are already visible at a low-power
magnification. In each area, the positive cells among 500
cells were counted using an eyepiece with a grid in a ×400
magnification. The Ki-67 index was calculated as the
percentage of positive cells by averaging the values
obtained for the two areas (count–Ki-67 index).
Recently, we demonstrated that the Ki-67 index assessed
by counting 2×500 cells in representative areas is a reliable
method to predict overall survival of MCL based on
patients treated within prospective randomized trials of the
European MCL Network [6]. Since this method has proven
its clinical significance, the Ki-67 index obtained by
counting (count–Ki-67 index) of 2×500 cells was consid-
ered the gold standard.
In order to reduce the number of counted cells in a
second independent experiment, ten cases were randomly
selected from the series. These cases were evaluated by four
observers (OD, IO, WK, and HHW) without knowledge of
the counted value. All observers counted the Ki-67-positive
cells among 100 lymphoma cells in five consecutive HPF
that had been selected as representative by each observer.
The values for the first to the fifth count of 100 cells were
registered separately.
Eyeballing
Eleven experienced expert hematopathologists evaluated all
cases at an onsite pathology panel meeting. Each patholo-
gist estimated the Ki-67 index independently in represen-
tative areas of the lymphoma chosen by the pathologist
himself and blinded for the results of the other investi-
gators.
Digital image analysis
Pictures of representative areas were obtained by the same
observers who performed the counting. The images were
analyzed blind (without knowledge of the results of
counting) by an independent observer using a KS400
system (Carl Zeiss, Jena, Germany). Automatic white
balance was performed and, subsequently, RGB color
thresholds were applied to identify positive and negative
nuclei. Fixed threshold values were used. Two values were
calculated: the percentage of positive nuclei and the
percentage of the area covered by the positive nuclei.
Statistical methods
To quantify the degree of agreement between the quantita-
tive Ki-67 values generated by counting, eyeballing, and
digital image analysis, concordance correlation coefficients
(CCC) were estimated (Lin 1989; Barnhart 2002). A CCC
of 1 indicates complete agreement, whereas a CCC of 0
indicates no correlation. To obtain 95% confidenceintervals,
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of two methods and bootstrap confidence limits were
estimated with 2,000 bootstrap samples for comparisons of
morethantwomethods.ThecalculationsusedtheSAS-macro
CCC provided online by the Department of Biostatistics and
Bioinformatics of the Duke University Medical Center,
Durham, NC, USA. Quantitative values were described with
median and range, and group comparisons for paired samples
were performed using the nonparametric signed rank test.
Single extreme values not representative for the range of
values were excluded. The working significance level was
5%.AllanalyseswereperformedusingSASVersion9.1(SAS
Institute, Cary, NC, USA).
Results
Gold standard
The Ki-67 index assessed by counting 2×500 cells showed
a median of 14.7% (minimum 2.1%, maximum 91%) in the
analyzed series. Two cases of highly proliferative lympho-
mas (Ki-67 index >80% by counting; see Fig. 1) had to be
excluded from further analysis in order to avoid the
detection of pseudocorrelations, resulting in a median of
14.6% and a maximum of 50.9%.
Estimation by eyeballing
The Ki-67 index estimated by eyeballing by 11
experienced hematopathologists deviated considerably
between individual observers (deviation up to 85%)
and from the count–Ki-67 index (deviation up to 72%;
Fig. 1). The concordance to the value obtained by
eyeballing compared to counting was poor (CCC between
0.29 and 0.61) and did not improve after averaging all
values for the 11 pathologists (CCC=0.53; Table 1). The
concordance between all 11 individual pathologists was
also poor (CCC=0.56).
Digital image analysis
Ki-67 values obtained by digital image analysis deviated
largely from the values obtained by counting. Values as
percentage of nuclei were 4.8% higher than the count–Ki-
67 index (median, p=0.034, signed rank test) and values as
percentage of area were 8.5% lower than the count–Ki-67
index (median, p=0.0011, signed rank test). The concor-
dance of digital image analysis with the count–Ki-67 index
was poor for both methods of analysis used (CCC 0.24 for
percentage of nuclei and 0.37 for percentage of positive
area; Table 2). All values as percentage of nuclei were
higher than the percentage of area values (p<0.0001,
Fig. 1 Variability of Ki-67 eyeballing. Plot of Ki-67 values estimated
by eyeballing by 11 experienced hematopathologists vs. Ki-67 values
obtained via counting of 2×500 cells (gold standard). Each patholo-
gist is represented by one color. In order to visualize identical
estimation values corresponding to the same counting values, counting
values are minimally scattered around the true values
Table 1 Values for the 11 pathologists
Measure P1 vs.
count
P2 vs.
count
P3 vs.
count
P4 vs.
count
P5 vs.
count
P6 vs.
count
P7 vs.
count
P8 vs.
count
P9 vs.
count
P10
vs.
count
P11
vs.
count
Mean
vs.
count
All
pathologists
N 27 27 27 27 27 26 25 24 24 27 27 27 22
CCC 0.61 0.38 0.38 0.61 0.55 0.49 0.46 0.31 0.54 0.51 0.29 0.53 0.56
95%
LCL
0.33 0.15 0.07 0.33 0.30 0.22 0.10 0.05 0.20 0.25 0.07 0.25 0.36
95%
UCL
0.79 0.58 0.62 0.79 0.73 0.68 0.71 0.54 0.77 0.70 0.49 0.73 0.68
P1–P11 pathologists 1–11, mean the mean of all pathologists, CCC concordance correlation coefficients, LCL lower confidence limit, UCL upper
confidence limit
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nuclei and percentage of area was low (CCC=0.46).
Counting 100 cells per representative area
In order to evaluate the effect of reducing the number
of counted cells on the interobserver concordance, 100
cells were counted in five consecutive HPF by four
observers in ten cases. Again, to avoid the detection of
pseudocorrelations, two cases with high Ki-67 values
had to be excluded from analysis. As expected, the
intraobserver concordance (CCC=0.83–0.96) was higher
than the interobserver concordance (CCC=0.68) if 100
cells in one HPF were counted. The concordance
between the observers increased with each additional
100 cells analyzed, with the strongest increase in
concordance between the first and the second HPF with
1×100 cells in each (CCC=0.68 and 0.74, respectively;
Table 3,F i g .2) and only minor improvement with further
increase or the number of cells to be counted. The
concordance with the gold standard of 2×500 counted
cells increased in average with each step of additional 100
cells counted. The average CCC for 2×100 compared to
the gold standard was 0.79. By counting more than 2×100
cells, a further relevant increase of the CCC with the gold
standard could be achieved in only two of four observers
(data not shown).
Discussion
Which specimens should be assessed for Ki-67?
Several studies have demonstrated the prognostic signifi-
cance of the Ki-67 index in MCL [6, 9, 11, 17–19, 21]. All
of these above-mentioned studies, including our own of the
European MCL Network, evaluated the Ki-67 index in the
primary biopsy specimens. To the best of our knowledge,
no studies analyzing the prognostic role of the Ki-67 index
in relapsed disease have been published so far. Thus, to
date, the use of the Ki-67 index as a prognostic marker has
only been proven in specimens obtained at primary
diagnosis. Of note, if tissues are fixed with Bouin’s
solution, an immunohistochemistry for Ki-67 is not
possible. Therefore, a fixation in buffered formalin solution
is mandatory.
In our study, we used lymph node specimens to evaluate
different methods of calculating the Ki-67 index. However,
other studies have also included extranodal biopsy speci-
mens. We generally recommend analysis of nodal and
extranodal specimens but not bone marrow (see below) to
evaluate the Ki-67 index. In any specimen, but especially in
extranodal specimens, only samples with dense lymphoma
areas should be analyzed because the Ki-67 index is based
on the percentage of Ki-67-positive lymphoma cells,
ignoring reactive background cells. Thus, minimally infil-
Measure % nuclei vs. count % area vs. count % nuclei vs. % area
N 27 27 27
CCC 0.24 0.37 0.46
95% LCL 0.00 0.04 0.25
95% UCL 0.47 0.62 0.63
Table 2 Values of percentage of
nuclei and percentage of area
CCC concordance correlation
coefficients
Fig. 2 Interobserver agreement
for Ki-67 assessment by count-
ing 1×100 to 5×100 cells and
using the average. The concor-
dance correlation coefficient
(CCC) was estimated with four
raters on eight samples
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reactive background should be excluded. The sample
size should allow a minimum of five independent HPF
(at ×400 magnification) to be selected for the counting.
Thus, a considerable percentage of punch needle biopsy
specimens is too small, especially since the selection of
a representative area is not possible in some cases (see
below).
All above-mentioned studies evaluated the Ki-67
index on histopathology slides. However, flow cytom-
etry is increasingly being used for nuclear antigens in
the diagnosis of lymphomas from blood and bone
marrow aspirates and lymph node fine needle aspirates
[2, 3]. The advantage of flow cytometry is the reliable
standardization of the method and the possibility to restrict
the measurement of proliferative index to the tumor cells
excluding reactive T cells from the analysis. Since the
majority of MCLs are leukemic [2], flow cytometry on
peripheral blood might represent an easily assessable
source for the Ki-67 analysis. However, in chronic
lymphocytic leukemia, Ki-67 values of peripheral blood
and lymph node compartment differs significantly as the
proliferative compartment probably resides predominantly
in solid tissues [15]. Therefore, future studies have to
evaluate whether Ki-67 staining of peripheral blood
cells and bone marrow are appropriate and representa-
tive for the proliferation in solid tissue and whether
flow cytometry of blood, bone marrow, or lymph node
biopsies may substitute for the Ki-67 index obtained by
histology on tissue sections. To date, the use of flow
cytometry of blood, bone marrow, and lymph nodes
cannot be regarded as a standard approach to assess the
K i - 6 7i n d e xi nM C L .
How should the Ki-67 index be assessed in MCL?
The Ki-67 index varies between different MCL subtypes
defined by cytology, with blastic and pleomorphic MCL
showing the highest proliferation on average [21].
However, there is great variability in the Ki-67 index
within the subgroup of classical MCL, with values
reaching up to the range found in blastic or pleomorphic
MCL [21]. Thus, the blastic or pleomorphic subtype of
MCL should only be diagnosed on the basis of cytology,
Table 3 Counting 100 cells per representative area
N CCC 95% CI
First 100 cells 8 0.68 0.54–0.79
First + second 100 cells (mean) 8 0.74 0.63–0.84
First–third 100 cells (mean) 8 0.76 0.63–0.84
First–fourth 100 cells (mean) 8 0.78 0.62–0.87
First–fifth 100 cells (mean) 8 0.80 0.68–0.88
CCC concordance correlation coefficients, CI confidence interval
Fig. 3 Areas of proliferating T
cells in the case of a classical
MCL. The MCL cells are char-
acterized by CD20 expression
and infiltrating T cells by stain-
ing for CD3. The Ki-67 index is
higher in the T cell-rich area
(corresponding areas are marked
by an arrow). Double staining
for CD20/Ki-67 of the T cell-
rich area at a higher magnifica-
tion shows numerous Ki-67
positive T cells (red) which are
negative for the B cell marker
CD20 (brown)
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of classical MCL, a high proliferation rate may also be
expected.
Digital image analysis is increasingly being used to
analyze immunohistochemical stainings in lymphoma
research and has been successfully applied to assess
the Ki-67 index in several solid tumors and lymphomas
[4, 20, 22]. However, we did not find a convincing
concordance of the digital image analysis with our gold
standard, the count–Ki-67 index. MCL are composed of
relatively small cells with a narrow rim of cytoplasm [1,
10, 21]. Since the lymphoma cells are usually densely
packed, currently available software for digital image
analysis often fails to recognize single nuclei. Never-
theless, we believe that future development may prove
digital image analysis to be a valuable tool for the
quantification of immunohistochemistry. Moreover, it is
theoretically possible that the Ki-67 values obtained by
digital image analysis might correlate with the clinical
outcome despite the poor correlation with the counted
value. Therefore, image analysis on a larger set of
lymphomas and a clinical correlation will be necessary
to finally solve this question.
As shown above, eyeballing and digital image
analysis (with the method used in this study) did not
show an acceptable concordance with the count–Ki-67
index and the interobserver correlation was poor. We
cannot rule out completely that estimation of the Ki-67
index by eyeballing might still be of relevance in the
future, since guidelines as reported herein and tools like
software for training of estimation (Y. Krivolapov,
personal communication) might improve the estimation
skills of pathologists. Whether the staining method/color
or the selection of the biopsy specimen influenced the
estimation performance of the pathologist has to be
determined in future studies. Although previous analysis
Fig. 4 Pitfalls in the selection
of representative areas for the
Ki-67 index in MCL. The upper
panel shows two examples of
Ki-67 staining. In the middle
panel, residual germinal centers
are marked by an arrow, hot
spots of proliferation by an
asterisk, and proliferating Tcells
by an arrowhead. In the lower
panel, suggested representative
areas for assessing the Ki-67
index are indicated by circles
J Hematopathol (2009) 2:103–111 109showed that the mitotic count did not reach the
predictive value of the Ki-67 index (data not shown),
future studies comparing these two methods are also
needed. To date, our results confirmed that quantitative
count of lymphoma cells at a high magnification
represents the method of choice to obtain the Ki-67
index and yields the best intraobserver and interobserver
reproducibility.
Counting 2×500 cells is very time-consuming and will
probably not be applicable in clinical routine. Thus,
various methods for the determination of the Ki-67
index were evaluated and compared to define the
optimal approach which provides reliable and reproduc-
ible results and can be used in multiobserver studies
with a minimum of workload. Accordingly, we evaluat-
ed the effect of reducing the number of counted cells on
the interobserver concordance. Increasing the number of
counted cells improved both interobserver and intra-
observer concordance, with the strongest increase in
concordance between 1×100 counted cells and 2×100
counted cells. The values obtained by counting 2×100
cells show a high concordance with the gold standard.
We thus recommend assessing the Ki-67 index in MCL
by counting the percentage of positive cells among 200
lymphoma cells in two independent, representative
lymphoma areas at a high magnification (HPF). This
method allows a reliable assessment of the Ki-67 index
in <2 min per case. The Ki-67 index in MCL can be
used as a continuous parameter or with cut-off values to
define risk groups [6, 9]. However, in any case, a reliable
Ki-67 value provided by the pathologist will be necessary.
Since Ki-67-positive cells are not homogenously distrib-
uted, the selection of representative lymphoma areas for the
counting of the Ki-67 index is of crucial importance.
Several areas of high proliferation should be excluded: (1)
“hot spots” of proliferation (see the “Materials and
methods” section for the definition), (2) T cells in the
periphery of lymphoma nodules (Fig. 3), and (3) residual
germinal centers. The pitfalls in the selection of represen-
tative areas in MCL are outlined in Fig. 4. “Hot spots” of
proliferation are not suitable to assess a prognostic Ki-67
value in MCL [21]. However, even if our guidelines are
followed, the selection of the representative area might still
have a subjective element.
We have to stress that the prognostic relevance of the Ki-
67 index in MCL so far has been proven only in
retrospective analysis. To date, the Ki-67 index has never
been applied as a stratifying marker for clinical decision
making. Therefore, the use of the Ki-67 index as a
prospectively evaluated factor for treatment stratification
has to be analyzed prospectively before a general use of this
marker outside of studies can be recommended. Neverthe-
less, the recommendations and guidelines presented in this
study will be of great importance for the design of such
future trials.
In summary, we recommend assessing the Ki-67 index
as a prognostic tool in MCL specimens:
& obtained at primary diagnosis before any treatment.
& from nodal sites but not from bone marrow. The
eligibility of biopsies from extranodal sites has to be
analyzed in future studies.
& of a minimum size that allows at least five independent
representative HPF to be selected.
& in 200 lymphoma cells, by counting the positive cells
among 100 lymphoma cells in two HPF each.
& in representative areas which do not include residual
germinal centers, hot spots of proliferation, or prolifer-
ating T cells.
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